Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 473494 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs BI 473494 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 06 Nov 2017 Status changed from recruiting to suspended.
- 22 Aug 2017 According to a Zealand Pharma media release, results are expected in late 2018.
- 01 Aug 2017 Planned End Date changed from 19 Jun 2018 to 25 Jun 2018.